Tempus AI, Inc.
TEMQ4 2024(TEM Q3 FY2024)Estimated27.8% AI
AI Revenue %
27.8%
AI Fair Value
$1.1B
AI Revenue (Q)
$106.8M
Total Revenue (Q)
$384.1M
Source: SEC EDGAR 10-Q Filing
View 10-Q on SEC.govAnalysis
Q3 FY2024: Genomics $116.4M, D&S $64.5M, Total $180.9M. AI from Genomics ($116.4M x 10% = $11.6M) + AI from D&S ($64.5M x 60% = $38.7M) = $50.3M / $180.9M = 27.8%. D&S share reached 35.7% — highest level — driven by strong data licensing and clinical trial demand. This was the peak AI revenue mix quarter before the Ambry acquisition diluted it.
Analyzed by claude-opus-4-6
Quoted Figures
Genomics $116,422, Data and services $64,507, Total net revenue $180,929 for three months ended September 30, 2024.
10-Q for period ending September 30, 2024 (Income Statement)
The Company recognized revenue for clinical orders of $105.2 million for the three months ended September 30, 2024. Genomics revenue for direct bill orders of $11.2 million.
10-Q for period ending September 30, 2024 (Revenue Recognition note)
AI Products Identified (Ring 1)
Lens AI platform (analytics)Intelligent DiagnosticsAlgorithmic clinical trial matchingDe-identified data licensing with AI curation
AI-Enabled Items (Ring 2 — Not Counted)
These items use AI but are not counted in the AI revenue estimate because they primarily serve non-AI functions.
Genomic sequencing (clinical orders $105.2M, direct bill $11.2M)Lab operations and clinical billing
Confidence Tier
EstimatedNo direct AI revenue disclosure — estimated from product mix